Status:
RECRUITING
Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE
Lead Sponsor:
Meyer Children's Hospital IRCCS
Conditions:
Systemic Lupus Erythematosus of Childhood
Eligibility:
All Genders
1-17 years
Phase:
NA
Brief Summary
Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the extent of renal damage. In...
Detailed Description
Pediatric systemic lupus erythematosus (SLE) (cSLE), compared with adult SLE, is characterized by a more severe phenotype, with more marked hematologic, neuropsychiatric, and renal changes. Lupus neph...
Eligibility Criteria
Inclusion
- Diagnosis of SLE arising before the age of majority (until the age of 18 years) according to SLICC and/or EULAR criteria 2019;
- Clinical, laboratory and/or histologic evidence of renal involvement manifested before the age of 18 years;
- Signature of informed consent.
Exclusion
- Onset of renal disease after the age of 18 years;
- SLE secondary to drugs or associated with other diseases such as systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, and other connectivities.
Key Trial Info
Start Date :
June 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06586710
Start Date
June 7 2023
End Date
December 31 2025
Last Update
September 19 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Meyer Children's Hospital IRCCS
Florence, Italy
2
IRCCS Gianna Gaslini
Genova, Italy
3
IRCCS Humanitas Research Hospital
Rozzano, Italy